Oncology
3 drugs are in development for Hepatocellular Carcinoma.
- Companies
- 3
- Clinical trials
- 65
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Hepatocellular Carcinoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| casdozokitug | Coherus Oncology, Inc. (CHRS) |
Phase 1(2)
About this indication
Hepatocellular Carcinoma context
Oncology·MeSH: Carcinoma, Hepatocellular (D006528)
Also known as: Adult Liver Cancer, Adult Liver Cancers, Carcinoma, Liver Cell, Carcinomas, Hepatocellular, Carcinomas, Liver Cell, Hepatoma, Hepatomas, Liver Cell Carcinoma, Adult
Prevalence
12.0 / 100K
Incidence
8.6 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Hepatocellular Carcinoma?
BioSniper tracks 3 drugs in development for Hepatocellular Carcinoma across 3 companies.
How many clinical trials target Hepatocellular Carcinoma?
There are 65 clinical trials targeting Hepatocellular Carcinoma tracked by BioSniper.
What is the prevalence of Hepatocellular Carcinoma?
The estimated prevalence of Hepatocellular Carcinoma is approximately 12.0 per 100,000 population.